Evrysdi is designed to work **everywhere,* every day**, and it's approved for **everyone with SMA**

Everywhere

SMA calls for whole-body treatment

That's why Evrysdi goes beyond the central nervous system and increases SMN protein throughout the body.*

*This was observed when Evrysdi was studied in animals.

Every day

Impact that lasts from one dose to the next†

Evrysdi works daily for a consistent impact on SMN protein levels.

†Based on studies of the concentration of Evrysdi in the blood over time.

Everyone

A treatment option for all people with SMA

Evrysdi is approved across all ages, SMA types, and abilities with no limitations of use.

Brooklyn, who is living with Type 2 SMA

See why Evrysdi is the most chosen treatment for SMA

More people treated for SMA take Evrysdi than any other SMA treatment, according to the 2024 Cure SMA State of SMA report.

SMA=spinal muscular atrophy; SMN=survival motor neuron.

What is Evrysdi?

Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in children and adults.

Important Safety Information

- **Before taking Evrysdi, tell your healthcare provider about all of your medical conditions, including if you:**
  - are pregnant or plan to become pregnant, as Evrysdi may harm your unborn baby. Ask your healthcare provider for advice before taking this medicine
  - are a woman who can become pregnant:
    - Before you start your treatment with Evrysdi, your healthcare provider may test you for pregnancy
    - Talk to your healthcare provider about birth control methods that may be right for you. Use birth control while on treatment and for at least 1 month after stopping Evrysdi

Please see accompanying full Prescribing Information for additional Important Safety Information.

Evrysdi®
risdiplam
60 mg powder for oral solution
5 mg tablet

— **Jose**, living with Type 2 SMA

Two non-invasive options offer **more flexibility**

Evrysdi comes in both liquid and tablet form*

Everyone's journey with SMA is different—that's why having options is important.

*Evrysdi 5-mg tablets are approved for people aged 2 years and older who weigh at least 44 lb (20 kg). They can be swallowed whole with water, mixed with non-chlorinated drinking water (eg, filtered water, bottled water), or the mixture can be taken with feeding tubes. Please refer to the Instructions for Use for liquid or tablet formulation of Evrysdi.

New to Evrysdi? See how it could fit your lifestyle

Important Safety Information (continued)

- **Pregnancy Registry.** There is a pregnancy registry for women who take Evrysdi during pregnancy. The purpose of this registry is to collect information about the health of the pregnant woman and her baby. If you are pregnant or become pregnant while receiving Evrysdi, tell your healthcare provider right away. Talk to your healthcare provider about registering with the Evrysdi Pregnancy Registry. Your healthcare provider can enroll you in this registry or you can enroll by calling 1-833-760-1098 or visiting https://www.evrysdipregnancyregistry.com.
  - are an adult male. Evrysdi may affect a man's ability to have children (fertility). Ask a healthcare provider for advice before taking this medicine
  - are breastfeeding or plan to breastfeed. It is not known if Evrysdi passes into breast milk and may harm your baby
- **Tell your healthcare provider about all the medicines you take**
- If you were prescribed Evrysdi for Oral Solution, you should receive Evrysdi from the pharmacy as a liquid. If the medicine in the bottle is a powder, **do not use it**. Contact your pharmacist for a replacement
- Avoid getting Evrysdi on your skin or in your eyes. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water
- **The most common side effects of Evrysdi include:**
  - For later-onset SMA: fever, diarrhea, rash
  - For infantile-onset SMA: fever; diarrhea; rash; runny nose, sneezing and sore throat (upper respiratory infection); lung infection (lower respiratory infection); constipation; vomiting; cough

These are not all of the possible side effects of Evrysdi. For more information on the risk and benefits profile of Evrysdi, ask your healthcare provider or pharmacist.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.

Genentech
A Member of the Roche Group

© 2026 Genentech USA, Inc. All rights reserved.
M-US-00029579(v2.0) 04/26

Evrysdi®
risdiplam
60 mg powder for oral solution
5 mg tablet